THE COMPANY
Founded in 2022, Rostra Therapeutics is a company developing innovative drug discovery technology created in the University of Strathclyde's Pure and Applied Chemistry department, and the Strathclyde Institute of Pharmacy and Biomedical Science. The Rostra team of two senior scientists and two senior commercial leaders is supported by a Scientific Advisory Board and virtual expert network focussed on efficiently developing novel anti-infective medicines. Rostra Therapeutic's initial goal is to develop specific 2nd generation S-MGBs through lead optimisation, up to pre-IND and onto phase I clinical development for the treatment of invasive fungal diseases. Rostra Therapeutics is driven by its vision to:
‘Restore health and save lives through innovative medicines'.
The Strathclyde Minor Groove Binder (S-MGB) platform was originally developed under the leadership of Professor Colin Suckling. The initial S-MGB concept dates back to 2003, and has been a dedicated research priority for the University of Strathclyde since then.
​
The Rostra Therapeutics team has been working together since July 2021, when commercial champion, Mr David Findlay, MBA was appointed by the University to help lead the commercialisation. David worked closely alongside Mr John Mulgrew, MBA formerly of the Innovation and Industry Engagement directorate at the University. After founding the company in 2022, directors David (CEO) and John (CSO) were joined on the board in 2024 by Professor Colin Suckling in the role of CSO. The core team is completed by Professor Iain Hunter acting as Senior scientific Advisor on biology and microbiology and pharmaceutical industry and investment finance experienced, Dr Stephane Mery as Non-executive Chair.
​
We are focused on accelerating the route to market through parallel development programmes, collaborations, and the use of accelerated regulatory routes. The 2nd generation S-MGBs have the potential to treat a variety of serious infections. Based on a clear unmet clinical need, positive data gathered to date, and a viable commercial market, Rostra Therapuetics' initial focus is on developing S-MGBs to treat serious fungal infections.